Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies. Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has the world’s largest selection of coronavirus research-grade products. GeoVax is at the forefront of development for a COVID-19 vaccine and its use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.
Commenting on the exclusive partnership, David A. Dodd, GeoVax Chairman & CEO stated, “We are delighted to establish this...
“GeoVax’s unique VLP-generation technology is exciting, and its commitment to the development of a vaccine for COVID-19 is inspiring. We at Sino Biological are honored to be the exclusive provider of COVID-19-related research reagents to assist their vaccine development efforts.”, commented Rob Burgess, Ph.D., Chief Business Officer for Sino Biological.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
